TEM - Tempus AI Inc
Executive Summary
Tempus AI Inc is a US-based technology company operating in the software-application segment of healthcare, where it applies artificial intelligence to clinical and molecular data with the stated aim of supporting precision-medicine workflows for oncology and other disease areas. The company combines a diagnostics business with a data and applications platform that licences de-identified, multi-modal clinical datasets to pharmaceutical and research customers. Tempus has positioned itself as one of the more visible independent players at the intersection of AI-driven healthcare data and clinical decision support, though it remains smaller and less diversified than the major diversified diagnostics incumbents.
The investment case rests on a series of hard, filing-disclosed catalysts that have already begun to print: the Personalis acquisition agreement, approximately USD200 million of new data and applications licensing wins disclosed with the Q2 2026 results, and raised full-year 2026 revenue guidance to USD1.595-1.605 billion. The next scheduled inflection point is the Q3 2026 earnings release, which should provide the first read on whether the licensing momentum is converting into a durable acceleration in Data and Applications revenue and whether the Personalis deal is tracking towards a closing in line with disclosed terms. The primary risk is that acquisition-closing and integration friction, combined with convertible-note dilution and a CEO-linked USD9.6 million share sale flagged in the research file, erode the upside even if operational execution remains on plan.
Bottom line - OPPORTUNISTIC BUY. Conviction Score: 59/100. The view would be upgraded towards a higher-conviction tier on evidence that Data and Applications revenue is sustaining growth in the mid-thirties percent range, that the Personalis deal closes on the disclosed terms, and that insider sales of the magnitude flagged do not recur; conversely, a downgrade would follow a slip in the licensing pipeline, a Personalis-related closing miss, or further large insider sales.
Thesis break: The thesis would be invalidated by a failure to close the Personalis acquisition on disclosed terms, Data and Applications revenue growth decelerating below 20% year on year for two consecutive quarters, or a further insider sale of comparable magnitude to the CEO-linked USD9.6 million transaction flagged in the research file.
Business Model
Tempus generates revenue from two principal streams: its Diagnostics business, which provides NGS-based and other molecular testing services to oncologists, hospitals, and other providers, and its Data and Applications business, which licences de-identified clinical and molecular datasets, AI models, and related software tools to pharmaceutical companies, biotechs, and academic researchers. The Diagnostics segment is volume-driven, with oncology test volumes disclosed as having grown 31% year on year in Q2 2026, while the Data and Applications segment is more contract-driven and tends to be lumpy around large enterprise licences.
The customer base is split between clinical payors and providers on the Diagnostics side and pharmaceutical, biotech, and academic customers on the Data and Applications side. The Data and Applications business is the higher-margin and faster-growing of the two, and the approximately USD200 million of new licences disclosed with Q2 2026 results is the most concrete evidence to date that this segment is scaling. Reported Q2 2026 revenue was USD382.5 million, up 22% year on year, with Data and Applications revenue disclosed as growing 36%, suggesting mix is gradually shifting towards the higher-quality revenue stream.
The competitive moat, to the extent one exists, rests on the scale and depth of the company's linked clinical-genomic database, the volume of testing flowing through the platform, and the resulting ability to train AI models on proprietary data that competitors cannot easily replicate. This is a defensible position in principle but is not unique by construction, and the company continues to operate at relatively thin GAAP margins. Q2 2026 GAAP net income was USD5.6 million and Adjusted EBITDA was USD8.0 million, indicating that profitability, while now positive at the quarterly level, remains modest and has not yet been demonstrated as durable. Cash and marketable securities of USD820.7 million at 30 June 2026 provide a runway, but convertible-note exposure remains a structural drag on per-share metrics.
Financial Snapshot
Recent Catalysts
[3 June 2026] - Tempus AI announced what its newsroom describes as a regulatory or clinical milestone, described in third-party coverage as an FDA-related win that helped drive a sharp share-price move on the day. Source: Tempus AI newsroom, referenced by CNN Markets and StocksToTrade coverage of the 4 June 2026 trading session.
[4 June 2026] - TEM shares traded up sharply in a single session, with third-party coverage attributing the move to the prior day's FDA-related news and to constructive AI-healthcare sentiment. Source: CNN Markets and StocksToTrade market commentary.
[1 June 2026] - Wolfe Research assumed coverage of TEM with a Peer Perform rating, per third-party reporting. Source: CNN Markets (Wolfe Research initiation as reported by TipRanks).
[30 July 2026] - Tempus reported Q2 2026 results via an 8-K and accompanying press release: Q2 revenue of USD382.5 million, up 22% year on year; oncology volume growth of 31%; Data and Applications revenue growth of 36%; approximately USD200 million of new Data and Applications licences signed; Q2 GAAP net income of USD5.6 million and Adjusted EBITDA of USD8.0 million; cash and marketable securities of USD820.7 million; and full-year 2026 revenue guidance raised to USD1.595-1.605 billion with Adjusted EBITDA guidance of approximately USD65 million. Source: Tempus AI 8-K and Exhibit 99.1 press release filed with the SEC on 30 July 2026.
[6 August 2026] - Tempus AI's next scheduled earnings announcement is 6 August 2026, after the close, per earnings-date tracking services. Source: TipRanks earnings calendar.
[Q3 2026, date to be confirmed] - Closing of the previously disclosed Personalis acquisition remains the next major M&A catalyst on the calendar, subject to customary closing conditions and any required approvals. Source: Personalis acquisition agreement disclosed in prior Tempus filings; closing date not confirmed in the provided research data.
Thesis Evaluation
Bull Case (25% weight)
Data and Applications revenue sustains growth above 35% as the disclosed approximately USD200 million of new licences ramps into recognised revenue, the Personalis acquisition closes on disclosed terms and contributes accretively, and full-year 2026 revenue lands towards the upper end of guided USD1.595-1.605 billion. With EBITDA tracking to roughly USD65 million and the multiple re-rating that licensing-led mix shift historically supports, a 12-month price target of $78 is plausible.
Base Case (50% weight)
Diagnostics volumes continue to compound at a high-twenties to low-thirties percent pace, Data and Applications revenue grows in the mid-thirties percent range as the new licences contribute a partial year, and the Personalis deal closes without material surprise. Full-year 2026 revenue prints near the midpoint of guidance, GAAP profitability remains thin, and the multiple holds broadly steady, supporting a 12-month price target of $60.
Bear Case (25% weight)
Acquisition-closing friction or integration issues at Personalis, a slip in the licensing pipeline, continued convertible-note dilution, and further insider sales of the magnitude flagged weigh on the multiple even if operational execution holds. In that scenario, growth decelerates towards the high teens and the multiple compresses, implying a 12-month downside target of $36.
Key Risks
- Acquisition closing and integration risk: The Personalis acquisition is subject to customary closing conditions and integration execution, and a failed or materially delayed close would remove a disclosed catalyst and force a re-rating. Estimated probability: 25%. Impact: severe.
- Convertible-note dilution: Outstanding convertible-note exposure continues to dilute per-share metrics and could be exacerbated by any future capital raise tied to the Personalis deal or working-capital needs. Estimated probability: 40%. Impact: moderate.
- Insider selling signal: A CEO-linked USD9.6 million share sale flagged in the research file is a direct negative signal, and any recurrence at similar magnitude would materially cap upside conviction. Estimated probability: 50%. Impact: moderate.
- Licensing pipeline lumpiness: Data and Applications revenue is contract-driven and lumpy, so a single quarter without a large enterprise licence win could materially reset growth expectations after the strong Q2 2026 print. Estimated probability: 30%. Impact: moderate.
- GAAP profitability durability: Q2 2026 GAAP net income of USD5.6 million and Adjusted EBITDA of USD8.0 million remain modest in absolute terms and have not yet been demonstrated as durable across multiple quarters. Estimated probability: 35%. Impact: moderate.
- Sentiment and multiple compression: AI-healthcare sentiment has historically been volatile, and a rotation away from the theme could compress the multiple even if operational delivery remains on plan. Estimated probability: 35%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: investors with a higher-risk tolerance, a holding period of at least 12 months to absorb clinical-data contract lumpiness and M&A integration noise, and an existing thematic allocation to AI-driven healthcare data who are comfortable with a name that is GAAP-profitable at the quarterly level but still structurally exposed to convertible-note dilution and insider-flow risk. The position size should reflect that this remains a mid-cap, sentiment-sensitive name rather than a core large-cap holding.
Avoid if: an investor requires a multi-year track record of durable GAAP profitability, cannot tolerate a single quarter of licensing-pipeline disappointment translating into a sharp re-rating, or is unwilling to hold through a potential Personalis-related closing delay. The combination of contract lumpiness, dilution overhang, and the insider-sale signal makes the name unsuitable for investors who need a clean, steadily compounding cash-flow story.
Recommendation
OPPORTUNISTIC BUY - 59/100. The hard, filing-disclosed catalysts - the Personalis agreement, the approximately USD200 million of new Data and Applications licences, and the raised full-year 2026 revenue guidance - support a modestly positive stance, but acquisition-closing risk, convertible-note dilution, and the CEO-linked USD9.6 million share sale cap conviction well below a high-conviction tier. The call would upgrade towards a stronger tier on evidence of sustained Data and Applications revenue growth in the mid-thirties percent range, a clean Personalis close, and an absence of further large insider sales; it would downgrade on a Personalis closing miss, a slip in the licensing pipeline, or renewed insider selling at similar magnitude. At the current price of $52.05 the shares trade above our buy ceiling of $44.00: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is $58.50, 12% above the current price of $52.05 - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below $44.00 - below this level the upside to the base-case target ($60.00) is at least 2x the downside to the bear case ($36.00), the minimum risk/reward we require before committing new capital.
between $44.00 and $60.00 - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above $60.00 - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 25%.
if the thesis would be invalidated by a failure to close the Personalis acquisition on disclosed terms, Data and Applications revenue growth decelerating below 20% year on year for two consecutive quarters, or a further insider sale of comparable magnitude to the CEO-linked USD9.6 million transaction flagged in the research file, regardless of price - the bear target of $36.00 is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 59/100. Trend versus prior report: Flat.
| Report date | Conviction |
|---|---|
| 2026-08-09 | 59 |
| 2026-07-25 | 59 |
| 2026-06-28 | 59 |
| 2026-05-30 | 54 |
| 2026-04-27 | 68 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow, company earnings releases, regulatory filings, investor day materials, third-party earnings-date tracking services, and sell-side analyst commentary as reported through mainstream financial news wires.
Primary source types: SEC filings (8-K dated 30 July 2026 and accompanying Exhibit 99.1 press release, prior periodic and current reports), company investor relations materials, public press releases, and third-party financial-news coverage of the FDA-related news flow and Wolfe Research initiation.
Key sources
- Investor Relations | Tempus AI
- Tempus AI (TEM) Earnings Date and Reports 2026 $TEM
- Tempus AI, Inc. (TEM) Stock Price, News, Quote & History - Yahoo Finance
- Tempus AI, Inc. (TEM) Stock Price, Quote, News & Analysis | Seeking Alpha
- Tempus Reports First Quarter 2026 Results
- Tempus Reports First Quarter 2026 Results - Tempus
- Why Tempus AI (TEM) Is Up 5.5% After Major USC Precision-Medicine Data Partnership News
- Can Tempus AI's (TEM) USC Partnership Quietly Redefine Its Clinical Data Moat? - Simply Wall St News
- News Releases | Tempus AI
- List of 5 Acquisitions by Tempus (Apr 2026) - Tracxn
Data correct as of 2026-08-09